NCT06465563

Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer

Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer: A Randomized, Open-label, Multicenter, Phase II Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With Cisplatin Plus Gemcitabine(CisGem), compared with Adebrelimab in Combination With CisGem, as first-line treatment in patients with Advanced Biliary Tract cancer.

Conditions

• Biliary Tract Cancer

Interventions

Type	Name	Description
DRUG	SHR-8068	SHR-8068
DRUG	Adebrelimab	Adebrelimab
DRUG	Cisplatin	Cisplatin
DRUG	Gemcitabine	Gemcitabine

Timeline

• Start date: 2024-07-01
• Primary completion: 2026-12-30
• Completion: 2026-12-30
• First posted: 2024-06-20
• Last updated: 2025-01-27

Locations

1 site across 1 country: China